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Our aim was to evaluate the influence of the hemodialysis
(HD) procedure in red blood cells (RBC) membrane protein
composition. We evaluated hematological data (RBC count,
hemoglobin concentration, and hematimetric indices) and RBC
membrane protein composition (linear and exponential gradient
polyacrylamide gel electrophoresis in the presence of sodium
dodecylsulfate [SDS-PAGE] followed by densitometry analysis
of RBC membrane proteins) before and immediately after the
HD procedure in 20 patients (10 responders and 10 non-responders
to recombinant human erythropoietin therapy [rhEPO]) and
26 healthy controls. Before HD, patients presented anaemia and
significant changes in membrane protein composition, namely, a
statistically significant reduction in spectrin associated with a
significant increase in bands 6, as well as an altered membrane
protein interaction (protein 4.1/spectrin, protein 4.1/band 3, protein
4.2/band 3 and spectrin/band 3). After HD, we found that patients
showed a statistically significant increase in RBC count and
hemoglobin, a further and statistically significant decrease in
spectrin, an increase in band 3, and an altered spectrin/band 3 ratio.
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When comparing responders and non-responders patients after
HD, we found that the non-responders presented a trend to a
higher reduction in spectrin. Our data suggest that HD procedure
seems to contribute to a reduction in spectrin, which is normally
associated with a reduction in RBC deformability, being that
reduction in spectrin is higher in non-responder patients.
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The red blood cell (RBC) membrane is a complex
structure comprising a lipidic bilayer, transmembrane or
integral proteins, and peripheral proteins, including the
cytoskeleton proteins. Modifications in RBC membrane
protein composition may account for changes in the
deformability of the cell, compromising its circulation in
the microvasculature and its survival.[1–3]
Spectrin is the major protein of the cytoskeleton, and
therefore most responsible for RBC shape, integrity, and
deformability. It links the cytoskeleton to the lipid bilayer
by vertical protein interactions with the transmembrane
proteins, band 3, and glycophorin C.[2,3] In the vertical
protein interaction of spectrin with band 3 are also
involved ankyrin (also known as band 2.1) and protein 4.2.
A normal linkage of spectrin with the other proteins of the
cytoskeleton assures normal horizontal protein interac-
tions, and its linkage with the transmembrane proteins
assures normal vertical interactions.[2,3]
Anaemia is a common complication in hemodialysis
(HD) patients, due mainly to a failure in erythropoietin
kidney production.[4] Moreover, the lifespan of RBCs of
HD patients being shortened is an additional cause of
anaemia in these patients.[5,6]
We recently reported[7] that HD patients present
changes in RBC membrane protein composition, the
decrease in spectrin being the most significant change.
This spectrin deficiency may account for a poorer link-
age of the cytoskeleton to the membrane, favoring
membrane vesiculation and probably a reduction in the
RBC lifespan of HD patients. We also found that HD
patient non-responders to recombinant human erythro-
poietin (rhEPO) therapy, receiving high doses of rhEPO
compared to responder’s patients, presented a trend to
lower values of spectrin, though without statistically
significance, and a significant increase in ankyrin that
resulted in a significant disturbance in horizontal and
vertical protein interactions, as suggested by the altered
ankyrin/band 3 and spectrin/ankyrin ratios. We have
hypothesized that alterations in RBC protein membrane
structure in HD patients could be related to the chronic
renal failure and/or to the HD procedure itself, and that
in non-responders, it could be also related to the higher
doses of rhEPO received by these patients. The aim of
our work was to evaluate the effect of HD procedure in
RBC membrane protein composition in HD patients,
including responders and non-responders to rhEPO
therapy.
We studied 20 HD patients (8 males, 12 females;
mean age 60.3 ± 16.7 years) under rhEPO treatment,
including 10 responders and 10 non-responders to rhEPO
therapy. Classification of the patients, as responders or
non-responders, was performed in accordance with the
European Best Practice Guidelines,[8] which defines
resistance to rhEPO as a failure to achieve target
hemoglobin (Hb) levels (between 11 and 12 g/dL) with
maintained doses of rhEPO higher than 300 IU/Kg/week
of epoetin or 1.5 μg/Kg/week of darbepoetin-α. The
two groups of patients were matched for age, gender,
weight, body mass index, mean time under HD, urea
reduction ratio, urea Ktv, and parathyroid hormone
serum levels.
HD patients were under therapeutic HD three times
per week, for 3 to 5 h, for a median period of time of
41 months. All patients used the high-flux polysulfone
FX-class dialyzers of Fresenius, 12 with FX60 and 8 with
FX80 dialyzer type. The causes of renal failure in patient’s
population were as follows: diabetic nephropathy (n = 5),
chronic glomerulonephritis (n = 3), hypertensive nephro-
sclerosis (n = 2), obstructive nephropathy (n = 1), neph-
rolithiasis (n = 1), chronic interstitial nephritis (n = 1), and
chronic renal failure of uncertain etiology (n = 7). Patients
with autoimmune disease, malignancy, hematological
disorders, and acute or chronic infection were excluded.
All patients gave their informed consent to participate in
this study.
Besides rhEPO therapy, all patients were under iron
and folate prophylactic therapies, in accordance to the
recommendations of European Best Practice Guidelines,[8]
to avoid nutrient erythropoietic deficiencies.
The control group included 26 healthy volunteers
presenting normal hematological and biochemical values,
with no history of renal or inflammatory diseases, and, as
far as possible, age- and gender-matched with HD
patients. Controls did not receive any medication known
to interfere with the studied variables.
Blood samples (using EDTA as anticoagulants) were
drawn from fasting controls or before and immediately after
the second dialysis session of the week in HD patients. We
evaluated hematological data (RBC count, Hb concentra-
tion, and hematimetric indices) by using an automatic
blood cell counter (Sysmex K1000; Sysmex, Hamburg,
Germany) and RBC membrane protein composition using
linear and exponential gradient polyacrylamide gel elec-
trophoresis in the presence of sodium dodecylsulfate
(SDS-PAGE) followed by development with Coomassie
brilliant blue R-250 (Sigma) and densitometric analysis, as
reported previously.[7]
For statistical analysis, we used the Statistical Package
for Social Sciences (SPSS version 15.0 for Windows,
SPSS, Inc., Chicago, Illinois, USA). Kolmogorov Smirnov
statistics were used to evaluate sample normality distribution.
Multiple comparisons between groups were performed
by one-way ANOVA supplemented with Turkey’s HSD
post-hoc test. For comparing data, before and after HD
procedure, paired-samples T-test or Wilcoxon test were
used. Significance was accepted at p less than 0.05.
The results were analyzed in order to study the
differences between healthy controls and HD patients,
to study changes imposed by the HD procedure, and
to study the differences between responders and non-
responders HD patients. In Table 1, we present the
hematological data and RBC membrane protein profile
for controls and HD patients (before and immediately
after HD).
Before HD, the patients presented anaemia, as shown
by the significantly decreased RBC count and Hb concen-
tration, with a significant increase in the mean cell volume
(MCV), mean cell Hb (MCH), and RBC distribution
width (RDW); statistically significant changes in membrane
Table 1 
Hematological data and RBC membrane protein profile for controls and HD patients
Controls (n = 26)
HD Patients (n = 20)
Before HD After HD
Hb (g/dL) 14.12 ± 1.27 11.94 ± 1.67* 12.98 ± 2.20*†
RBC (×1012/L) 4.72 ± 0.59 3.78 ± 0.61* 4.13 ± 0.84†
MCV (fl) 92.00 (90.00–94.00) 93.00 (90.25–98.00)* 93.35 (93.00–98.00)*
MCH (pg) 29.83 ± 1.39 31.83 ± 2.05* 31.60 ±1.94*
MCHC (g/dL) 32.47 ± 0.58 32.39 ± 0.71 32.13 ± 0.79
RDW (%) 12.79 ± 0.52 14.84 ± 1.11* 14.77 ± 1.19*
Spectrin (%) 27.63 (26.41–28.79) 25.58 (24.10–27.07)* 24.47 (22.31–26.95)*†
Ankyrin (%) 6.97 ± 1.62 6.39 ± 1.55 6.23 ± 1.28
Band 3 (%) 38.57 ± 3.99 38.10 ± 3.78 41.13 ± 2.44*†
Protein 4.1 (%) 7.56 ± 1.45 6.48 ± 1.60 6.39 ± 1.69
Protein 4.2 (%) 5.51 ± 0.72 4.34 ± 0.99 4.84 ± 1.04
Band 5 (%) 6.82 ± 0.86 6.56 ± 0.91 6.71 ± 0.59
Band 6 (%) 5.19 ± 1.04 6.46 ± 0.87* 6.17 ± 1.15*
Band 7 (%) 2.20 ± 0.65 2.09 ± 0.43 2.37 ± 0.34
Protein 4.1/spectrin 0.276 ± 0.624 0.243 ± 0.070* 0.251 ± 0.081*
Protein 4.1/band 3 0.192 (0.154–0.227) 0.170 (0.138–0.206)* 0.163 (0.121–0.202)*
Protein 4.2/band 3 0.149 (0.125–0.162) 0.114 (0.101–0.133)* 0.118 (0.101–0.147)*
Spectrin/band 3 0.707 (0.649–0.822) 0.685 (0.626–0.796)* 0.647 (0.566–0.689)*†
Ankyrin/band 3 0.185 ± 0.585 0.171 ± 0.049 0.152 ± 0.330*
Spectrin/ankirin 4.18 ± 1.07 4.48 ± 1.361 4.45 ± 1.49
*p < 0.05 vs. controls, †p < 0.05 vs. before HD. Results are presented as mean ± standard deviation and as
median (interquartile ranges).
Abbreviations: Hb = hemoglobin concentration, RBC = red blood cell count, MCV = mean cell volume,
MCH = mean cell hemoglobin, MCHC = mean cell hemoglobin concentration, RDW = red cell distribution width.
protein composition were observed, namely, a reduction in
spectrin and an increase in band 6. Though only slight
changes were observed in the other proteins, the ratios
between them, reflecting altered horizontal and vertical
protein interactions—protein 4.1/spectrin, protein 4.1/band 3,
protein 4.2/band 3 and spectrin/band 3—were observed.
After dialysis, HD patients showed a statistical signifi-
cant increase in RBC count and Hb concentration; no
statistical significant changes were found in the other hemato-
logical parameters (see Table 1). Concerning the RBC mem-
brane protein profile, a statistically significant decrease in
spectrin, an increase in band 3, and an altered spectrin/band
3 ratio were found after HD procedure. We also observed
after HD some trends toward the control profile (band 6 and
band 7) and some trends in opposition to control profile
(a further decrease in ankyrin, protein 4.1, protein 4.2, and
band 5). We must notice that band 3 increased and reached a
statistically significantly higher value than that presented by
the control. Most of the ratios, reflecting protein interactions,
presented values that were still different from those of the
control.
When comparing the two groups of HD patients
(responders and non-responders), we did not find signifi-
cant changes in membrane protein profile, excepting that
non-responders presented a trend (p = 0.124) to a higher
reduction in spectrin membrane content (see Figure 1).
It is accepted that the HD procedure is able to pro-
mote a complex biological response when the patient’s
blood interacts with the artificial HD membranes.[9–13]
However, the effect of HD procedure in RBC membrane
protein content has not been adequately defined.
In the present study, despite rhEPO therapy,
anaemia was a consistent finding in our HD patients.
This anaemia was associated with a statistically signifi-
cant increase in RDW, suggesting the presence of
anisocytic RBCs. Higher Hb levels and RBC counts
were found after HD. This increase in circulating RBCs
has been described[14,15] to be associated with a translo-
cation of RBCs from the splanchnic circulation (and
possibly from the splenic circulation) in order to
compensate the hypovolemic stress during dialysis
ultrafiltration.
The changes observed in the RBC membrane protein
composition of HD patients (see Table 1), when compared
to controls, were similar to those we have recently
reported,[7] namely, a statistically significant reduction in
spectrin and in band 6 (no significant change was observed
for band 7). The lower number of patients enrolled in
the present study may explain the slighter differences in
protein profile and in the ratios reflecting membrane
protein interactions. We still found in the present study
disturbed horizontal (protein 4.1/spectrin) and vertical
(protein 4.1/band 3; protein 4.2/band 3; spectrin/band 3)
interactions, suggesting a disturbance in membrane
deformability and integrity. Spectrin deficiency may
account for a poorer linkage of the cytoskeleton to the
membrane, favoring membrane vesiculation and probably
a reduction in the RBC lifespan of HD patients.[1,2] The
increase in protein band 6 may further reflect an altered
membrane protein interaction and destabilization of mem-
brane structure.
When studying the differences in membrane protein
composition imposed by the HD procedure, the results
showed some trends toward a control pattern profile for
some of the membrane proteins—bands 3, 6, and 7. Spec-
trin showed an even lower value after HD, and ankyrin,
protein 4.1, protein 4.2, and band 5 also present a trend
toward decreasing. The analysis of the ratios reflecting
the protein interactions remained altered, when compared
to controls; however, when comparing the ratios before
and after HD, only the ratio spectrin/band 3 showed a
statistically significant value, reflecting a vertical membrane
protein disturbance. However, no statistically significant
correlation between the RBC membrane protein alterations
and the RBC counts and hemoglobin levels were found,
which can be due to the lower patients number included in
this study.
Moreover, we also found that this spectrin reduction
is enhanced in the non-responder group (see Figure 1),
which can be associated with an enhanced inflammation
process. Indeed, results from our and other groups[16]
have demonstrated that HD and particularly resistance to
Figure 1. Spectrin reduction (%) in responders and non-responders 
HD patients.
rhEPO therapy are associated with a pronounced inflam-
matory response, demonstrated by higher levels of C-reactive
protein (data not shown). However, no statistically signif-
icant differences were found between C-reactive protein
levels and RBC membrane protein modifications found
during HD procedure. We also should not exclude the
possibility that the much higher doses of rhEPO used in
non-responders, can be also involved in RBC membrane
protein alterations.
In conclusion, the HD procedure seems to contribute
to a reduction in spectrin, which is normally associated
with a reduction in RBC deformability, being enhanced in
non-responder patients. Therefore, we cannot exclude that
the inflammatory product, being enhanced in HD patients
(especially in non-responders) may play a role in RBC
membrane protein disturbance.
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